Quantcast
Last updated on April 17, 2014 at 14:51 EDT

Latest Immunosuppressants Stories

2013-10-21 08:29:21

People on biologic or systemic drugs should only receive inactivated vaccines PORTLAND, Ore., Oct. 21, 2013 /PRNewswire-USNewswire/ -- National Psoriasis Foundation (NPF) Medical Board recommends that people with psoriasis and psoriatic arthritis only receive inactivated flu vaccines while on drugs that suppress the immune system. People should talk with their doctors about vaccinations before starting immunosuppressive treatments, such as biologic or systemic drugs, the medical board...

2013-10-18 08:24:23

Approval represents the fourth U.S. indication for Cimzia® ATLANTA, Oct. 18, 2013 /PRNewswire/ -- regulated information - UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia(®) (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis (AS). The FDA also issued a Complete Response Letter relating to the supplemental Biologics License Application (sBLA) of Cimzia(®) for the treatment of adults with active axial spondyloarthritis...

2013-10-17 23:19:38

Reportbuyer.com just published a new market research report: Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth. London (PRWEB) October 17, 2013 Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Summary GBI Research, the leading business intelligence provider, has released its latest research, “Multiple Sclerosis...

2013-10-17 12:27:45

Surveyed Physicians Report that Payer Hurdles are Not the Only Obstacles to Prescribing Xeljanz, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 17, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that approximately one-half of surveyed rheumatologists and payers report that they believe Pfizer's Xeljanz has a comparable effect on the signs and symptoms of...

2013-10-16 23:31:55

Neurological Wellness Center physicians encourage persons with mild to moderate Alzheimer’s disease to participate. Participants will be given weekly injections plus nutritional supplements that may suppress inflammatory processes associated with Alzheimer’s disease. (PRWEB) October 16, 2013 Many people receiving this treatment report a clearing of brain fog within minutes of receiving this injection. Pre-treatment and post-treatment cognitive function testing is utilized to document...

2013-10-14 23:21:18

Reportbuyer.com just published a new market research report: PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) October 14, 2013 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - UK Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective,...

2013-10-10 08:26:50

Oral Agents Could Alter the Treatment Algorithm, After Establishing Clinical Profiles at Least Comparable to TNF-alpha Inhibitors, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market will experience moderate growth over the next decade as sales increase from $12.3 billion in...

2013-10-09 12:26:03

Key Drivers of Market Growth Will Be the Uptake of Humira, Simponi, Vedolizumab and Tofacitinib, According to Findings from Decision Resources BURLINGTON, Mass., Oct. 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ulcerative colitis drug market will increase from $2.1 billion in 2012 to $3.6 billion in 2022 in the United States, France, Germany, Italy, Spain, the...

2013-10-03 08:29:05

-- The post-hoc analysis applies a new measurement tool created by AbbVie to assess the efficacy of HS therapy NORTH CHICAGO, Ill., Oct. 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA(®) (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.(1) Efficacy results were reported using a novel Hidradenitis Suppurativa...

2013-10-02 23:33:35

Pharmaceutical research companies are now investigating or developing 81 Alzheimer’s drugs.* A blockbuster treatment for moderate to severe Alzheimer’s is still more than ten years away according to Rolando Hernandez neurosurgeon for Neurological Wellness Center. (PRWEB) October 02, 2013 Pharmaceutical research has banked heavily on the beta amyloid hypothesis. The recent failures of bapineuzumab and solanezumab in phase III clinical trials has forced researchers to question weather...